As of pre-market trading on August 6th, Hutchmed (China) on the US stock market rose more than 7%, to $19.52; its listed in Hong Kong shares rose more than 7.2% today. In terms of news, the report released by CMB International pointed out that the tumor and immune drug revenue of Hutchmed (China) reached $0.128 billion in the first half of the year, a year-on-year increase of 59.6%, including $43 million in sales from fruquintinib overseas. CMB International maintains its "buy" rating on Hutchmed (China). Considering the strong sales momentum of fruquintinib in the United States and its listing in overseas areas outside of China in the short term, the target price has been raised from HKD 34.31 to HKD 35.61.
美股异动｜和黄医药盘前涨超7% 招银国际上调H股目标价并维持“买入”评级
US stocks change: Hutchmed (China) rose more than 7% in pre-market trading. CMB International raised its target price for H shares and maintained a 'buy' rating.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated